Quest Diagnostics (DGX) has reported consecutive growth considerably, with a delivered gain of 60% from an investment five years ago. The stock has valued Bokf Na's holdings to $5.94 million showing considerable appeal to value investors. In a series of strategic acquisitions, Quest has acquired
LifeLabs from OMERS, further expanded to access in
Diagnostic Innovation, and acquired outreach laboratory services from various healthcare providers including OhioHealth, University Hospitals, and Allina Health. Their strategic expansion allows for increased diagnostic access particularly in Ohio and Canada. Notably, Quest acquisition of select
PathAI Diagnostics' Lab assets has accelerated the adoption of AI and Digital Pathology, optimizing cancer diagnosis. With Q2 earnings surpassing expectations, DGX improves its 2024 outlook and raises its full-year guidance. It has made significant progress towards Responsible Corporate Citizenship, seen in their 2023 Corporate Responsibility Report. Moreover, successfully incorporating broader clinical labs to test developmental delays and signing a collaboration with Fitbit, the company has expanded its services and displayed its capacity for innovation.
Quest Diagnostics DGX News Analytics from Sun, 10 Oct 2021 03:13:33 GMT to Fri, 13 Sep 2024 10:03:20 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 5
